A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

[ad_1] In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how…

WSJ News Exclusive | The New Green Investment: Getting Clean Energy to Big Cities

[ad_1] U.S. cities racing to cut their emissions are facing a roadblock: They can’t access the wind and solar power being developed in remote sites hundreds of miles away. Now…

Can a Big Pharma Ever Be Worth $1 Trillion?

[ad_1] There are five tech companies valued at over $1 trillion. In healthcare, the closest contender is Eli Lilly. This year it became the first big pharmaceutical to surpass a…

Wegovy-Maker Novo Nordisk to Spend More Than $2 Billion Boosting Production in France

[ad_1] Pharmaceutical giant Novo Nordisk said it will invest more than 16 billion Danish kroner ($2.34 billion) in its French production site as it seeks to meet rising demand for…

Wegovy Maker Novo Nordisk to Spend $6 Billion Boosting Production Capacity

[ad_1] Novo Nordisk, the Danish pharmaceutical giant that makes the blockbuster Wegovy obesity drug, said it will invest more than $6 billion to boost production capacity. Copyright ©2023 Dow Jones…

Obesity Drug Demand Outstrips Supply

[ad_1] Eli Lilly’s blockbuster diabetes medication Mounjaro is expected to receive Food and Drug Administration approval as an obesity treatment before the end of the year, which would lead to…

Never Mind Covid, Investors Want a Pfizer Obesity Pill

[ad_1] Some of this year’s best performers in the healthcare sector are companies expected to profit from the anti-obesity drug craze, with Eli Lilly and Novo Nordisk shares both up…

Ozempic Maker Novo Nordisk Has a Weight Problem

[ad_1] Oct. 23, 2023 11:39 am ET The company behind diabetes and obesity phenomena Ozempic and Wegovy is overweight. Novo Nordisk became Europe’s most valuable company last month, overtaking luxury…

Stocks Clinch Four-Day Winning Streak

[ad_1] Long-term Treasury yields continued to ease. [ad_2] Source link

America’s Food Giants Confront the Ozempic Era

[ad_1] Nearly 7% of the U.S. population is projected to be on weight-loss drugs in 2035. [ad_2] Source link